K Danø

1.5k total citations
8 papers, 1.3k citations indexed

About

K Danø is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, K Danø has authored 8 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Cancer Research, 4 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in K Danø's work include Protease and Inhibitor Mechanisms (7 papers), Peptidase Inhibition and Analysis (3 papers) and TGF-β signaling in diseases (2 papers). K Danø is often cited by papers focused on Protease and Inhibitor Mechanisms (7 papers), Peptidase Inhibition and Analysis (3 papers) and TGF-β signaling in diseases (2 papers). K Danø collaborates with scholars based in Denmark. K Danø's co-authors include Elisabeth Ralfkiær, Karl Tryggvason, Charles Pyke, J Grøndahl-Hansen, John Rømer, Sirpa Salo, Christian Rosenquist, H.T. Mouridsen, I. J. Christensen and M Blichert-Toft and has published in prestigious journals such as FEBS Letters, International Journal of Cancer and PubMed.

In The Last Decade

K Danø

8 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K Danø Denmark 8 854 607 549 425 249 8 1.3k
Yves A. De Clerck United States 11 643 0.8× 577 1.0× 188 0.3× 370 0.9× 208 0.8× 14 1.1k
Julie C. Lively United States 8 769 0.9× 455 0.7× 1.0k 1.8× 1.3k 3.1× 212 0.9× 8 2.0k
J Pöllänen Finland 12 1.4k 1.6× 449 0.7× 514 0.9× 551 1.3× 870 3.5× 14 1.7k
Anna T. Levy United States 7 820 1.0× 604 1.0× 277 0.5× 477 1.1× 241 1.0× 8 1.2k
Sirpa Salo Finland 19 341 0.4× 420 0.7× 602 1.1× 464 1.1× 77 0.3× 33 1.3k
John Nip United States 15 277 0.3× 443 0.7× 249 0.5× 980 2.3× 417 1.7× 24 1.4k
Salomón Matías‐Román Spain 7 478 0.6× 344 0.6× 281 0.5× 312 0.7× 185 0.7× 7 812
Jeannette E. Williams United States 6 263 0.3× 306 0.5× 379 0.7× 429 1.0× 53 0.2× 9 855
Ruediger Volk United States 8 501 0.6× 148 0.2× 380 0.7× 861 2.0× 71 0.3× 8 1.2k
Kimberley Howarth United Kingdom 15 384 0.4× 347 0.6× 272 0.5× 631 1.5× 138 0.6× 20 1.4k

Countries citing papers authored by K Danø

Since Specialization
Citations

This map shows the geographic impact of K Danø's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K Danø with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K Danø more than expected).

Fields of papers citing papers by K Danø

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K Danø. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K Danø. The network helps show where K Danø may publish in the future.

Co-authorship network of co-authors of K Danø

This figure shows the co-authorship network connecting the top 25 collaborators of K Danø. A scholar is included among the top collaborators of K Danø based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K Danø. K Danø is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Sehested, Maxwell, et al.. (1997). Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer.. PubMed. 77(4). 345–55. 85 indexed citations
2.
Behrendt, Niels & K Danø. (1996). Effect of purified, soluble urokinase receptor on the plasminogen‐prourokinase activation system. FEBS Letters. 393(1). 31–36. 16 indexed citations
3.
Nielsen, Boye Schnack, Susanne Timshel, Lars Kjeldsen, et al.. (1996). 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. International Journal of Cancer. 65(1). 57–62. 147 indexed citations
4.
Salo, Sirpa, et al.. (1995). Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.. PubMed. 55(18). 4132–9. 341 indexed citations
5.
Grøndahl-Hansen, J, I. J. Christensen, Christian Rosenquist, et al.. (1993). High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.. PubMed. 53(11). 2513–21. 353 indexed citations
6.
Lund, Leif R. & K Danø. (1992). Okadaic acid strongly increases gene transcription, mRNA and protein level for the urokinase receptor in human A549 cells. FEBS Letters. 298(2-3). 177–181. 10 indexed citations
7.
Pyke, Charles, et al.. (1992). Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization.. PubMed. 52(5). 1336–41. 292 indexed citations
8.
Grøndahl-Hansen, J, et al.. (1988). Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.. PubMed. 111(1). 42–51. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026